App-Quantinova.ai

Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1 alphais associated with poor prognosis in hepatocellular carcinoma patients post TACE procedure.

Mingsheng Huang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Comparison of a new prognostic system and six current staging systems in predicting the survival rate of patients with advanced hepatocellular carcinoma undergoing loco-regional therapy.

Ying-Fen Hong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Efficacy and cost-effectiveness of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.

Qiu Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Sorafenib

Chinese medicine based study of warm and removing decoction in combination with conventional therapy of hepatic cell carcinoma.

Yongling Gong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Methadone hydrochloride

Comprehensive genomic characterization of hepatocellular carcinoma to reveal novel therapeutic targets.

Yuewei Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Function and mechanism investigation of NOP14 in the metastatic cascades of pancreatic cancer.

Yongxing Du - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Lymphocyte-to-monocyte ratio for predicting gemcitabine containing chemotherapy outcomes in pancreatic cancer patients.

Liwei Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Gemcitabine

Anlotinib in metastatic renal cell carcinoma (mRCC) with a previous anti-VEGFR TKI: Preliminary results from a multicenter, phase II trial.

Ai-Ping Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic Renal Cell Cancer

anlotinib

Irf7 as a novel marker for predicting bone metastases of primary prostate cancer.

Zhao Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bone metastases

N/A

Phase III randomized trial of comparing chemoradiotherapy vs. radiotherapy alone in lymph node negative patients with early-stage cervical cancer following radical hysterectomy.

Congying Xie - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cervical cancer

Paclitaxel

A phase I dose-escalation study of BGB-290, a novel PARP1/2 selective inhibitor in patients with advanced solid tumors.

Jason D. Lickliter - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

BGB-290

Pre-judgement significance of endometrial echo complex in postmenopausal type 2 endometrial cancer.

Yi Zhu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Endometrial Cancer

N/A

Importance of -Catenin for cancer stem cell generation and tumorigenic activity in nasopharyngeal carcinoma.

Rui Jiang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Nasopharyngeal carcinoma

N/A

Recombinant human adenovirus p53 injection enhanced sensitivity of chemotherapeutics through DNA damage response pathway in advanced papillary thyroid cancer in vitro and in vivo.

Jingqiang Zhu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Papillary carcinoma

Paclitaxel

Recombinant human adenovirus p53 injection (rAd-p53) is a challenge for anaplastic thyroid cancer treatment.

Wenshuang Wu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thyroid Cancer

Paclitaxel

Oxaliplatin plus fluorouracil/leucovorin or sorafneib as first-line treatments for advanced hepatocellular carcinoma: a cost-effectiveness analysis.

Pengfei Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Fluorouracil

UNC13D G863D as a genetic predisposition factor of lymphoma and a founder mutation in Chinese.

Hongxing Liu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

N/A

Prognostic factors of advanced Hodgkins lymphoma: multivariate analysis of 199 Chinese patients with long-term follow-up.

Qin Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Roxithromycin

A new prognostic model for nasal-type, extranodal natural killer/T cell lymphoma.

Na Li - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

T-cell lymphoma

N/A

Synergistic cytotoxic effects of selinexor and chloroquine phosphate in mantle cell lymphoma.

Yongyi Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mantle cell lymphoma

chloroquine

Filters

24782 Abstracts